Skip to contentV
Viridian Therapeutics, Inc.
V
VRDNViridian Therapeutics, Inc. Q2 2018 · 10-Q
Revenue$2.18M$2.18M+203.9% vs Q2 2017 Net Income-$8.71M-$8.71MN/M vs Q2 2017 EPS Diluted-$0.29-$0.29N/M vs Q2 2017 Operating Income-$8,861,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$4,600,000N/M Margins · derivedOperating margin-406.1%+617.6 pt vs Q2 2017
Net margin-399.4%+619.0 pt vs Q2 2017
ended Jun 30, 2018 · filed Aug 8, 2018 · 39 d after period end